9 Biotechnology Stocks to Buy Now

EPZM, STML, PCYC, ACOR, NWBO, CMRX, BMRN, SGEN, AMGN improve in weekly rankings

   
9 Biotechnology Stocks to Buy Now

This week, nine biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Epizyme, Inc. (EPZM) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. In Portfolio Grader’s specific subcategories of Earnings Momentum and Sales Growth, EPZM also gets A’s. Shares of the stock have been changing hands at an unusually rapid pace, four times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

This week, Stemline Therapeutics, Inc. (STML) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). For more information, get Portfolio Grader’s complete analysis of STML stock.

Pharmacyclics, Inc. (PCYC) boosts its rating from a C to a B this week. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

Acorda Therapeutics, Inc. (ACOR) shows solid improvement this week. The company’s rating rises from a C to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

This week, Northwest Biotherapeutics, Inc. (NWBO) pushes up from a C to a B rating. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. Shares of the stock have been trading at an exceptionally rapid pace, up fourfold from the week prior. For more information, get Portfolio Grader’s complete analysis of NWBO stock.

Chimerix, Inc.’s (CMRX) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of CMRX stock.

This week, BioMarin Pharmaceutical’s (BMRN) ratings are up from a C last week to a B. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

The rating of Seattle Genetics, Inc. (SGEN) moves up this week, rising from a C to a B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Amgen (AMGN) gets a higher grade this week, advancing from a B last week to an A. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. At present, the stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2014/08/9-biotechnology-stocks-to-buy-now-epzm-stml-pcyc/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.